Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.

MLA

Glamuzina, Emma, et al. “Treatment of Mucopolysaccharidosis Type II (Hunter Syndrome) with Idursulfase: The Relevance of Clinical Trial End Points.” Journal of Inherited Metabolic Disease, vol. 34, no. 3, June 2011, pp. 749–54. EBSCOhost, https://doi.org/10.1007/s10545-011-9280-1.

APA

Glamuzina, E., Fettes, E., Bainbridge, K., Crook, V., Finnegan, N., Abulhoul, L., & Vellodi, A. (2011). Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. Journal of Inherited Metabolic Disease, 34(3), 749–754. https://doi.org/10.1007/s10545-011-9280-1

Chicago

Glamuzina, Emma, Emma Fettes, Katie Bainbridge, Victoria Crook, Niamh Finnegan, Lara Abulhoul, and Ashok Vellodi. 2011. “Treatment of Mucopolysaccharidosis Type II (Hunter Syndrome) with Idursulfase: The Relevance of Clinical Trial End Points.” Journal of Inherited Metabolic Disease 34 (3): 749–54. doi:10.1007/s10545-011-9280-1.